Literature DB >> 8603376

Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates.

J L Urdiales1, P Morata, I Núñez De Castro, F Sánchez-Jiménez.   

Abstract

The biological effects of dehydrodidemnin B(DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB). Daily administration of DB or DDB (2.5 micrograms/mouse) almost duplicated the animal life-span and total number of tumour cells decreased by 70-90%. Results suggest a major effect of DDB when administered in the lag phase of growth. DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by DDB-treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603376     DOI: 10.1016/0304-3835(96)04151-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  36 in total

1.  In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Ronald D van Ooijen; Irma Meijerman; Luis Lopez Lazaro; Ignacio Manzanares; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

Review 2.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

3.  Synthetic studies of tamandarin B side chain analogues.

Authors:  Kenneth M Lassen; Jisun Lee; Madeleine M Joullié
Journal:  J Org Chem       Date:  2010-05-07       Impact factor: 4.354

4.  Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors.

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Phytochem Rev       Date:  2009-06       Impact factor: 5.374

5.  Optimization of the culture condition for an antitumor bacterium Serratia proteamacula 657 and identification of the active compounds.

Authors:  Li Miao; Xueling Wang; Wei Jiang; Shengping Yang; Huiru Zhou; Youpeng Zhai; Xiaojian Zhou; Kunming Dong
Journal:  World J Microbiol Biotechnol       Date:  2012-12-28       Impact factor: 3.312

Review 6.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

Review 7.  Biosynthesis of depsipeptides, or Depsi: The peptides with varied generations.

Authors:  Diego A Alonzo; T Martin Schmeing
Journal:  Protein Sci       Date:  2020-11-02       Impact factor: 6.725

8.  Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab.

Authors:  Nora M Barboza; Daniel J Medina; Tulin Budak-Alpdogan; Miguel Aracil; José M Jimeno; Joseph R Bertino; Debabrata Banerjee
Journal:  Cancer Biol Ther       Date:  2012-01-15       Impact factor: 4.742

9.  Inhibition of translation by cytotrienin A--a member of the ansamycin family.

Authors:  Lisa Lindqvist; Francis Robert; William Merrick; Hideaki Kakeya; Christopher Fraser; Hiroyuki Osada; Jerry Pelletier
Journal:  RNA       Date:  2010-10-13       Impact factor: 4.942

Review 10.  Novel molecules as the emerging trends in cancer treatment: an update.

Authors:  Priyanka Sekar; Raashmi Ravitchandirane; Sofia Khanam; Nethaji Muniraj; Ananda Vayaravel Cassinadane
Journal:  Med Oncol       Date:  2022-01-04       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.